Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Sep 15, 2011 - Intellipharmaceutics' partnership with Par Pharmaceuticalgoes back several years. ..... with Paragraph IV certification for aranolazine generic version of Ranexa (ranolazine) extended-release

Well it's not going to get 180 days exclusivity, because Lupin is also marketing the 2 doses along with patent owner Gilead... but since there are only 2 marketing this extended version of ranolazine, and it's an $854 million market, it sure would be nice to be the 3rd one out there... and I think FDA would give this one priority to expand competition.

Nice work everyone who dug this up... This Ranexa generic has the potential of becoming a very meaningful windfall.